{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:20:58Z","timestamp":1790706058456,"version":"4.1.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2013,2,12]],"date-time":"2013-02-12T00:00:00Z","timestamp":1360627200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background.<\/jats:title><jats:p>The purpose of the study was to estimate the impact on survival and fracture rates of the use of zoledronic acid versus no use (or delayed use) in the adjuvant treatment of patients with early-stage (stages I\u2013III) breast cancer.<\/jats:p><\/jats:sec><jats:sec><jats:title>Materials and Methods.<\/jats:title><jats:p>We performed a systematic review and meta-analysis of randomized clinical trials. Trials were located through PubMed, ISI, Cochrane Library, and major cancer scientific meeting searches. All trials that randomized patients with primary breast cancer to undergo adjuvant treatment with zoledronic acid versus nonuse, placebo, or delayed use of zoledronic acid as treatment to individuals who develop osteoporosis were considered eligible. Standard meta-analytic procedures were used to analyze the study outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results.<\/jats:title><jats:p>Fifteen studies were considered eligible and were further analyzed. The use of zoledronic acid resulted in a statistically significant better overall survival outcome (five studies, 6,414 patients; hazard ratio [HR], 0.81; 95% confidence interval [CI], 0.70\u20130.94). No significant differences were found for the disease-free survival outcome (seven studies, 7,541 patients; HR, 0.86; 95% CI, 0.70\u20131.06) or incidence of bone metastases (seven studies, 7,543 patients; odds ratio [OR], 0.94; 95% CI, 0.64\u20131.37). Treatment with zoledronic acid led to a significantly lower overall fracture rate (OR, 0.78; 95% CI, 0.63\u20130.96). Finally, the rate of osteonecrosis of the jaw was 0.52%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion.<\/jats:title><jats:p>Zoledronic acid as adjuvant therapy in breast cancer patients appears to not only reduce the fracture risk but also offer a survival benefit over placebo or no treatment.<\/jats:p><\/jats:sec>","DOI":"10.1634\/theoncologist.2012-0261","type":"journal-article","created":{"date-parts":[[2013,2,13]],"date-time":"2013-02-13T05:18:52Z","timestamp":1360732732000},"page":"353-361","source":"Crossref","is-referenced-by-count":75,"title":["Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis"],"prefix":"10.1093","volume":"18","author":[{"given":"Antonis","family":"Valachis","sequence":"first","affiliation":[{"name":"a Department of Oncology, General Hospital of Eskilstuna, Eskilstuna, Sweden;"},{"name":"b University of Uppsala, Uppsala, Sweden;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos P.","family":"Polyzos","sequence":"additional","affiliation":[{"name":"c Centre for Reproductive Medicine, Universitair Ziekenhuis Brussel, Vrije Universiteit Brussel, Brussels, Belgium;"},{"name":"d Section of Oncology and Obstetrics\/Gynecology, Panhellenic Association for Continual Medical Research (PACMeR), Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Coleman","sequence":"additional","affiliation":[{"name":"e Academic Unit of Clinical Oncology, Weston Park Hospital, CR-UK\/YCR Sheffield Cancer Research Centre, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gnant","sequence":"additional","affiliation":[{"name":"f Department of Surgery and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holger","family":"Eidtmann","sequence":"additional","affiliation":[{"name":"g Department of Gynecology and Obstetrics, University Medical Center Schleswig-Holstein, Kiel, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam M.","family":"Brufsky","sequence":"additional","affiliation":[{"name":"h Division of Medicine, University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, Pennsylvania, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Aft","sequence":"additional","affiliation":[{"name":"i Department of Surgery, Washington University Medical School, St. Louis, Missouri, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amye J.","family":"Tevaarwerk","sequence":"additional","affiliation":[{"name":"j University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Swenson","sequence":"additional","affiliation":[{"name":"k Oncology Research Department, Park Nicollet Institute, Minneapolis, Minnesota, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pehr","family":"Lind","sequence":"additional","affiliation":[{"name":"a Department of Oncology, General Hospital of Eskilstuna, Eskilstuna, Sweden;"},{"name":"l Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Mauri","sequence":"additional","affiliation":[{"name":"d Section of Oncology and Obstetrics\/Gynecology, Panhellenic Association for Continual Medical Research (PACMeR), Athens, Greece;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2013,2,12]]},"reference":[{"key":"2021122308350039500_B1","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1172\/JCI118722","article-title":"Bisphosphonates: Mechanisms of action","volume":"97","author":"Rodan","year":"1996","journal-title":"J Clin Invest"},{"key":"2021122308350039500_B2","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.semarthrit.2010.06.001","article-title":"The efficacy of bisphosphonates in the prevention of vertebral, hip, and nonvertebral-nonhip fractures in osteoporosis: A network meta-analysis","volume":"40","author":"Jansen","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"2021122308350039500_B3","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.clinthera.2009.05.009","article-title":"Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: A meta-analysis of randomized clinical trials","volume":"31","author":"Machado","year":"2009","journal-title":"Clin Ther"},{"key":"2021122308350039500_B4","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1093\/jnci\/djk054","article-title":"Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis","volume":"99","author":"Daubin\u00e9","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"2021122308350039500_B5","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1172\/JCI118841","article-title":"Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro","volume":"98","author":"Pluijm","year":"1996","journal-title":"J Clin Invest"},{"key":"2021122308350039500_B6","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1054\/bjoc.1999.1131","article-title":"Bisphosphonates induce apoptosis in human breast cancer cell lines","volume":"82","author":"Senaratne","year":"2000","journal-title":"Br J Cancer"},{"key":"2021122308350039500_B7","first-page":"6538","article-title":"Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats","volume":"62","author":"Fournier","year":"2002","journal-title":"Cancer Res"},{"key":"2021122308350039500_B8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.6004\/jnccn.2010.0020","article-title":"Does adjuvant bisphosphonate in early breast cancer modify the natural course of the disease? A meta-analysis of randomized controlled trials","volume":"8","author":"Mauri","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"2021122308350039500_B9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ygyno.2009.12.001","article-title":"Lack of evidence for fracture prevention in early breast cancer bisphosphonate trials: A meta-analysis","volume":"117","author":"Valachis","year":"2010","journal-title":"Gynecol Oncol"},{"key":"2021122308350039500_B10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3816\/CBC.2009.n.015","article-title":"Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results","volume":"9","author":"Brufsky","year":"2009","journal-title":"Clin Breast Cancer"},{"key":"2021122308350039500_B11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/S1470-2045(08)70204-3","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy","volume":"9","author":"Gnant","year":"2008","journal-title":"Lancet Oncol"},{"key":"2021122308350039500_B12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10549-010-1201-8","article-title":"Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: A phase III trial of the Korean Cancer Study Group (KCSG-BR06\u201301)","volume":"125","author":"Kim","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308350039500_B13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1210\/jc.2009-1366","article-title":"Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment","volume":"95","author":"Hershman","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308350039500_B14","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","article-title":"Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite","volume":"38","author":"Nancollas","year":"2006","journal-title":"Bone"},{"key":"2021122308350039500_B15","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.bone.2007.03.002","article-title":"Determinants of structure\u2013function relationships among bisphosphonates","volume":"40","author":"Russell","year":"2007","journal-title":"Bone"},{"key":"2021122308350039500_B16","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.canlet.2006.03.011","article-title":"Differential effects of bisphosphonates on breast cancer cell lines","volume":"246","author":"Verdijk","year":"2007","journal-title":"Cancer Lett"},{"key":"2021122308350039500_B17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2021122308350039500_B18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s10549-009-0432-z","article-title":"Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: A meta-analysis","volume":"116","author":"Mauri","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308350039500_B19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1745-6215-8-16","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis","volume":"8","author":"Tierney","year":"2007","journal-title":"Trials"},{"key":"2021122308350039500_B20","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1105195","article-title":"Breast-cancer adjuvant therapy with zoledronic acid","volume":"365","author":"Coleman","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308350039500_B21","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/S1470-2045(11)70122-X","article-title":"Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial","volume":"12","author":"Gnant","year":"2011","journal-title":"Lancet Oncol"},{"key":"2021122308350039500_B22","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1093\/annonc\/mdq217","article-title":"Efficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST study","volume":"21","author":"Eidtmann","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308350039500_B23","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1002\/cncr.26313","article-title":"Final 5-year results of Z-FAST trial: Adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole","volume":"118","author":"Brufsky","year":"2012","journal-title":"Cancer"},{"key":"2021122308350039500_B24","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10549-009-0332-2","article-title":"Immediate versus delayed zoledronic acid for prevention of bone loss in postmenopausal women with breast cancer starting letrozole after tamoxifen-N03CC","volume":"117","author":"Hines","year":"2009","journal-title":"Breast Cancer Res Treat"},{"issue":"24 suppl","key":"2021122308350039500_B25","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1158\/0008-5472.SABCS-09-4082","article-title":"Impact of Zoledronic Acid in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST","volume":"69","author":"Coleman","year":"2009","journal-title":"Cancer Res"},{"key":"2021122308350039500_B26","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1200\/JCO.2008.18.6213","article-title":"Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: The HOBOE trial","volume":"27","author":"Rossi","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308350039500_B27","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s10549-012-1973-0","article-title":"Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results","volume":"133","author":"Takahashi","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"2021122308350039500_B28","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S1470-2045(10)70054-1","article-title":"Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: An open label, randomised, phase 2 trial","volume":"11","author":"Aft","year":"2010","journal-title":"Lancet Oncol"},{"key":"2021122308350039500_B29","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000334456","article-title":"The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: A prospective, randomized, phase II trial","volume":"81","author":"Safra","year":"2011","journal-title":"Oncology"},{"issue":"24 suppl","key":"2021122308350039500_B30","first-page":"P2","article-title":"Influence of zoledronic acid on BMD in premenopausal women with breast cancer and neoadjuvant or adjuvant chemotherapy and\/or endocrine treatment \u2013 the ProBone studies","volume":"71","author":"Hadji","year":"2011","journal-title":"Cancer Res"},{"key":"2021122308350039500_B31","doi-asserted-by":"crossref","first-page":"471","DOI":"10.3816\/CBC.2010.n.062","article-title":"Randomized trial of adjuvant zoledronic acid in postmenopausal women with high-risk breast cancer","volume":"10","author":"Leal","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"2021122308350039500_B32","first-page":"101","article-title":"Effects of exercise vs bisphosphonates on bone mineral density in breast cancer patients receiving chemotherapy","volume":"7","author":"Swenson","year":"2009","journal-title":"J Support Oncol"},{"issue":"24 suppl","key":"2021122308350039500_B33","first-page":"S1","article-title":"Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor\u2013positive early breast cancer","volume":"71","author":"Gnant","year":"2011","journal-title":"Cancer Res"},{"issue":"24 suppl","key":"2021122308350039500_B34","first-page":"S1","article-title":"Long-term survival outcomes among postmenopausal women with hormone receptor-positive early breast cancer receiving adjuvant letrozole and zoledronic acid: 5-Year follow-up of ZO-FAST","volume":"71","author":"Boer","year":"2011","journal-title":"Cancer Res"},{"key":"2021122308350039500_B35","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1093\/annonc\/mdr159","article-title":"Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: Implications for adjuvant therapy of breast cancer","volume":"23","author":"Gallo","year":"2012","journal-title":"Ann Oncol"},{"key":"2021122308350039500_B36","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jama.2009.50","article-title":"Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women","volume":"301","author":"Bliuc","year":"2009","journal-title":"JAMA"},{"key":"2021122308350039500_B37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/cncr.11892","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"2021122308350039500_B38","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: A randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"2021122308350039500_B39","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","article-title":"First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised controlled trial","volume":"376","author":"Morgan","year":"2010","journal-title":"Lancet"},{"key":"2021122308350039500_B40","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ejca.2011.10.021","article-title":"The efficacy of zoledronic acid in breast cancer adjuvant therapy: A meta-analysis of randomised controlled trials","volume":"48","author":"Yan","year":"2012","journal-title":"Eur J Cancer"},{"key":"2021122308350039500_B41","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(97)08468-7","article-title":"Summing up evidence: One answer is not always enough","volume":"351","author":"Lau","year":"1998","journal-title":"Lancet"},{"key":"2021122308350039500_B42","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1740774508100984","article-title":"Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials","volume":"6","author":"Jones","year":"2009","journal-title":"Clin Trials"},{"key":"2021122308350039500_B43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1471-2288-7-5","article-title":"Inclusion of zero total event trials in meta-analyses maintains analytic consistency and incorporates all available data","volume":"7","author":"Friedrich","year":"2007","journal-title":"BMC Med Res Methodol"},{"key":"2021122308350039500_B44","doi-asserted-by":"crossref","first-page":"c7017","DOI":"10.1136\/bmj.c7017","article-title":"Obstetric outcomes after treatment of periodontal disease during pregnancy: Systematic review and meta-analysis","volume":"341","author":"Polyzos","year":"2010","journal-title":"BMJ"},{"key":"2021122308350039500_B45","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1001\/jama.287.22.2973","article-title":"Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials","volume":"287","author":"Balk","year":"2002","journal-title":"JAMA"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2012-0261","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2012-0261","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/4\/353\/41856755\/oncolo_18_4_353.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/18\/4\/353\/41856755\/oncolo_18_4_353.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T12:01:51Z","timestamp":1688040111000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/18\/4\/353\/6398743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,12]]},"references-count":45,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2013,2,12]]},"published-print":{"date-parts":[[2013,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2012-0261","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2013,4,1]]},"published":{"date-parts":[[2013,2,12]]}}}